T/FIF, a New Plateau Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (2049)	5/29/2003 11:41:05 AM
From: Icebrg	Read Replies (2) of 2243

>>>>Spectrum Pharmaceuticals (SPPI)>>>> Time for an update on one of the moon-shot candidates. Spectrum was kind enough to email me a copy of their Annual Report. It is not on the website yet. Not the boring 10K-stuff, but the multicolored version.( From the PDF-file it was not possible to decide where the 10K should be fitted. So I put them side by side in the file archive). OK, there are a couple of things I need to read through and there was one thing I wanted to have confirmed. The report was supposed to include a mini-update on EOquin, their second cancer drug. And yes, there was one. We are currently running a phase 1-2 study of Eoquin™ (formerly Neoquin) in superficial bladder cancer. To date, five patients have been enrolled in the study and three have completed treatment. Each of these three patients have achieved complete remission (or complete disappearance of their tumors). We plan to enroll approximately 25 patients in this study by the end of 2003. Eoquin is a prodrug which is activated by special enzymes present in high amounts in cancer cells. The activated form of Eoquin kills tumor cells with less risk of harming normal body cells. This unique mode of action has led to E o q u i n ’s clinical use in the treatment of superficial bladder cancer. Three out of three is not bad. I wonder what is so special about this type of cancer? I don't know anything about the protocol (yet). I will have to try to find out. One possibility is that these are patients that have had their cancer resected and are treated with EOquin as an adjuvant in order to mop up whatever might have been left behind by the knife. So it is perhaps a little bit to early to call this a break-through. It might just be the work of a very good surgeon. I will continue to keep you informed unless there are howls of protests. (Sometimes I feel almost like a pump-and-dump artist about these very frequent updates . Things are supposed to be very slow-moving in this part of the economy). Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next